The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

1993-02

AUTHORS

H Modjtahedi, J M Styles, C J Dean

ABSTRACT

Using the breast carcinoma cell line MDA-MB 468 as immunogen, we have produced six new rat monoclonal antibodies (mAbs) against the human EGF receptor (EGFR) and are investigating their use for diagnostic and therapeutic applications in cancer patients whose tumours overexpress these receptors. The mAbs (three IgG2b and one each of IgG2a, IgG1 and IgA) were selected on the basis that they bound to the extracellular domain of the EGFR and blocked growth factor-receptor interaction. Competitive assays showed that, with the exception of antibody ICR65, the mAbs bound to one of two distinct epitopes on the external domain of the EGFR. ICR65, however, cross-reacted with mAbs binding to both epitopes. All of the mAbs immunoprecipitated the 170 kDa glycoprotein from cells expressing the EGFR but not the 185 kDa product of the related c-erbB-2 proto-oncogene. Unlike EGF and TGF alpha none of the mAbs stimulated the growth of quiescent human foreskin fibroblasts but they inhibited the EGF and TGF alpha induced growth stimulation of these cells in vitro. When tested for their effect on tumour cells the mAbs were found to inhibit the growth in vitro of a number of human tumours that overexpressed the EGFR (e.g. HN5, HN6, HN15, A431, MDA-MB 468) but they were without effect on tumour cell lines expressing low or undetectable amounts of the receptor. Our initial results indicate that this new generation of antibodies which bind with high affinity to the EGFR, block growth factor-receptor interaction and inhibit the growth of human squamous carcinoma cell lines overexpressing the receptor have potential for clinical application. More... »

PAGES

247

References to SciGraph publications

Journal

TITLE

British Journal of Cancer

ISSUE

2

VOLUME

67

Author Affiliations

Related Patents

  • Methods Of Generating Variant Proteins With Increased Host String Content
  • Treatment Method Using Egfr Antibodies And Src Inhibitors And Related Formulations
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dual Specific Binding Proteins Directed Against Il-1 And/Or Il-17
  • Diagnostic Markers
  • Cancer Therapy
  • Heterodimeric Antibodies To Cd3 X Cd123
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Combination Anti-Cancer Therapy
  • Heterodimeric Proteins
  • Molecular Biomarkers For Predicting Response To Tyrosine Kinase Inhibitors In Lung Cancer
  • Specific Binding Proteins And Uses Thereof
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Il-1 Binding Proteins
  • Rapid Clearance Of Antigen Complexes Using Novel Antibodies
  • Antibodies With Modified Isoelectric Points
  • Il-1 Binding Proteins
  • Compositions And Methods For Simultaneous Bivalent And Monovalent Co-Engagement Of Antigens
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Use Of Anti-Egfr Antibodies In Treatment Of Egfr Mutant Mediated Disease
  • Il-1 Binding Proteins
  • Molecular Biomarkers For Predicting Response To Antitumor Treatment In Lung Cancer
  • Antibodies Against Platelet-Derived Growth Factor (Pdgf)
  • Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
  • Molecular Biomarkers For Predicting Response To Tyrosine Kinase Inhibitors In Lung Cancer
  • Nscle Combination Therapy
  • Specific Binding Proteins And Uses Thereof
  • Heterodimeric Proteins
  • Anti-Dll4/Vegf Dual Variable Domain Immunoglobulin And Uses Thereof
  • Combination Cancer Therapy Comprising Administration Of An Egfr Inhibitor And An Igf-1r Inhibitor
  • Methods Of Generating Variant Antibodies With Increased Host String Content
  • Diagnostic Methylation Markers Of Epithelial Or Mesenchymal Phenotype And Response To Egfr Kinase Inhibitor In Tumours Or Tumour Cells
  • Il-1 Binding Proteins
  • Il-1 Binding Proteins
  • Biological Markers Predictive Of Anti-Cancer Response To Epidermal Growth Factor Receptor Kinase Inhibitors
  • Molecular Biomarkers For Predicting Response To Antitumor Treatment In Lung Cancer
  • Heterodimeric Proteins
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-17 Binding Proteins
  • Il-17 Binding Proteins
  • Methods For The Identification Of Agents That Inhibit Mesenchymal-Like Tumor Cells Or Their Formation
  • Combination Anti-Cancer Therapy
  • Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
  • Catecholic Butanes And Use Thereof For Cancer Therapy
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-17 Binding Proteins
  • Use Of Emt Gene Signatures In Cancer Drug Discovery, Diagnostics, And Treatment
  • Heterodimeric Antibodies To Cd3 X Cd20
  • Dual Variable Domain Immunoglobulin And Uses Thereof
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-1 Binding Proteins
  • Prostaglandin E2 Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-I Binding Proteins
  • Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors In Hepatocellular Carcinoma
  • Monoclonal Antibody 175 Targeting The Egf Receptor And Derivatives And Uses Thereof
  • Method And Pharmaceutical Composition For Use In The Treatment Of Chronic Liver Diseases Associated With A Low Hepcidin Expression
  • Method And Compositions For Treating Cancer And Related Methods
  • Method And Compositions For Treating Cancer And Related Methods
  • Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1
  • Molecular Biomarkers For Predicting Response To Tyrosine Kinase Inhibitors In Lung Cancer
  • Biological Markers Predictive Of Anti-Cancer Response To Epidermal Growth Factor Receptor Kinase Inhibitors
  • In Situ Methods For Monitoring The Emt Status Of Tumor Cells In Vivo
  • Biological Markers Predictive Of Anti-Cancer Response To Insulin-Like Growth Factor-1 Receptor Kinase Inhibitors
  • Dual Specific Binding Proteins Directed Against Il-1Β And/Or Il-17
  • Bispecific Antibodies That Bind To Cd38 And Cd3
  • Dual Specific Binding Proteins Directed Against Il-13 And Il-17
  • Dual Variable Domain Immunoglobulins And Uses Thereof
  • Il-1 Binding Proteins
  • Cancer Therapy
  • Methods For Protein Screening
  • Il-17 Binding Proteins
  • Il-17 Binding Proteins
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/bjc.1993.48

    DOI

    http://dx.doi.org/10.1038/bjc.1993.48

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1037345733

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/8094290


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Breast Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Division", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cross Reactions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Epidermal Growth Factor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "ErbB Receptors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Fibroblasts", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hybridomas", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunoglobulin G", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Proto-Oncogene Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats, Inbred Strains", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats, Nude", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptor, ErbB-2", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Transforming Growth Factor alpha", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Tumor Cells, Cultured", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vulvar Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Institute of Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.18886.3f", 
              "name": [
                "Section of Immunology, Institute of Cancer Research, Sutton, Surrey, UK."
              ], 
              "type": "Organization"
            }, 
            "familyName": "Modjtahedi", 
            "givenName": "H", 
            "id": "sg:person.01056410041.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056410041.13"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Styles", 
            "givenName": "J M", 
            "id": "sg:person.01200253670.41", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200253670.41"
            ], 
            "type": "Person"
          }, 
          {
            "familyName": "Dean", 
            "givenName": "C J", 
            "id": "sg:person.0637732460.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637732460.22"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1073/pnas.78.12.7535", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000954068"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0003-9861(87)90062-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001570577"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0006-291x(78)91322-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002672775"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01741322", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004298551", 
              "https://doi.org/10.1007/bf01741322"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf01741322", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004298551", 
              "https://doi.org/10.1007/bf01741322"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/313745a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010441557", 
              "https://doi.org/10.1038/313745a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/path.1711490104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010503247"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/path.1711490104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010503247"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(84)90337-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013930186"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(84)90337-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013930186"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1128/mcb.7.1.251", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014751899"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ijc.2910450219", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021662420"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(90)90801-k", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037771370"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0076-6879(87)46009-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037834946"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/mrd.1080270104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040872441"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/ijc.2910450124", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044614689"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1172/jci111463", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045385068"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(84)90435-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045400812"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0022-1759(84)90435-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045400812"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0006-291x(85)90131-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048416200"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1002/jcb.240200207", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052427608"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/0092-8674(87)90592-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1054549968"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.3500513", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1062618084"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.6324343", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1062636774"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1210/mend-3-11-1830", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064330421"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077279988", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1077337747", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/oxfordjournals.bmb.a072464", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1077677559"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1078475424", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1078868051", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079264608", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079500151", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079508043", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079509297", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079543285", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1079767004", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1080064417", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081564232", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1081683249", 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "1993-02", 
        "datePublishedReg": "1993-02-01", 
        "description": "Using the breast carcinoma cell line MDA-MB 468 as immunogen, we have produced six new rat monoclonal antibodies (mAbs) against the human EGF receptor (EGFR) and are investigating their use for diagnostic and therapeutic applications in cancer patients whose tumours overexpress these receptors. The mAbs (three IgG2b and one each of IgG2a, IgG1 and IgA) were selected on the basis that they bound to the extracellular domain of the EGFR and blocked growth factor-receptor interaction. Competitive assays showed that, with the exception of antibody ICR65, the mAbs bound to one of two distinct epitopes on the external domain of the EGFR. ICR65, however, cross-reacted with mAbs binding to both epitopes. All of the mAbs immunoprecipitated the 170 kDa glycoprotein from cells expressing the EGFR but not the 185 kDa product of the related c-erbB-2 proto-oncogene. Unlike EGF and TGF alpha none of the mAbs stimulated the growth of quiescent human foreskin fibroblasts but they inhibited the EGF and TGF alpha induced growth stimulation of these cells in vitro. When tested for their effect on tumour cells the mAbs were found to inhibit the growth in vitro of a number of human tumours that overexpressed the EGFR (e.g. HN5, HN6, HN15, A431, MDA-MB 468) but they were without effect on tumour cell lines expressing low or undetectable amounts of the receptor. Our initial results indicate that this new generation of antibodies which bind with high affinity to the EGFR, block growth factor-receptor interaction and inhibit the growth of human squamous carcinoma cell lines overexpressing the receptor have potential for clinical application.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1038/bjc.1993.48", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1017082", 
            "issn": [
              "0007-0920", 
              "1532-1827"
            ], 
            "name": "British Journal of Cancer", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "67"
          }
        ], 
        "name": "The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468", 
        "pagination": "247", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "b1e69b00510c029c8b59bf64793b4ce23ca5f1fffb54f1d0db84012bd4a927b5"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "8094290"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "0370635"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/bjc.1993.48"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1037345733"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/bjc.1993.48", 
          "https://app.dimensions.ai/details/publication/pub.1037345733"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T11:55", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000359_0000000359/records_29207_00000002.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://www.nature.com/articles/bjc199348"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/bjc.1993.48'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/bjc.1993.48'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/bjc.1993.48'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/bjc.1993.48'


     

    This table displays all metadata directly associated to this object as RDF triples.

    259 TRIPLES      21 PREDICATES      85 URIs      42 LITERALS      30 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/bjc.1993.48 schema:about N017ea951cb7c44e1bb2242e4bb4fceb8
    2 N01e050d9faca4b0abccb373a05773336
    3 N24b751acce444c6cb9d8b7af3a015be8
    4 N28b0cbde4f0447828454d374aeed5426
    5 N3454487b040c4e9c8f57a3abba937050
    6 N4575624772df4420b36c1ec557c9c601
    7 N6ba8f68ab4b84ea7b71c2ab0023c7281
    8 N6c4fa3f9afef457e92fe85915e1001d8
    9 N77a1e6ab00fb4a21a34a11d7f0fc2e24
    10 N88405fe97bce4608a2e490c89e91fa5f
    11 N93c86e5f164e40cf90bc6040494914fc
    12 Na040518ac941497787caa8ec6e24e815
    13 Na1b53ed9fd41457aac4e5773f4e4f3bd
    14 Nb01c7d260e5244cc99fb108c3ec4b6cc
    15 Nd8914655bffa40188587d41192eaa605
    16 Ne0093110a1244df69d7355ebddace48e
    17 Ne428f38f637c439493d85a92fbd20c0b
    18 Ne725714f08eb434cbb72fcb9c07ca578
    19 Ne9691047603441d7aa64b5bb32fd8fbc
    20 Ne9c5d2f943144fdab3d398938695ba09
    21 Nfc00ce6ee2784562a723479697dad713
    22 anzsrc-for:11
    23 anzsrc-for:1112
    24 schema:author Nf12615c3367d48ffbe5c12aca28d6bb8
    25 schema:citation sg:pub.10.1007/bf01741322
    26 sg:pub.10.1038/313745a0
    27 https://app.dimensions.ai/details/publication/pub.1077279988
    28 https://app.dimensions.ai/details/publication/pub.1077337747
    29 https://app.dimensions.ai/details/publication/pub.1078475424
    30 https://app.dimensions.ai/details/publication/pub.1078868051
    31 https://app.dimensions.ai/details/publication/pub.1079264608
    32 https://app.dimensions.ai/details/publication/pub.1079500151
    33 https://app.dimensions.ai/details/publication/pub.1079508043
    34 https://app.dimensions.ai/details/publication/pub.1079509297
    35 https://app.dimensions.ai/details/publication/pub.1079543285
    36 https://app.dimensions.ai/details/publication/pub.1079767004
    37 https://app.dimensions.ai/details/publication/pub.1080064417
    38 https://app.dimensions.ai/details/publication/pub.1081564232
    39 https://app.dimensions.ai/details/publication/pub.1081683249
    40 https://doi.org/10.1002/ijc.2910450124
    41 https://doi.org/10.1002/ijc.2910450219
    42 https://doi.org/10.1002/jcb.240200207
    43 https://doi.org/10.1002/mrd.1080270104
    44 https://doi.org/10.1002/path.1711490104
    45 https://doi.org/10.1016/0003-9861(87)90062-2
    46 https://doi.org/10.1016/0006-291x(78)91322-0
    47 https://doi.org/10.1016/0006-291x(85)90131-7
    48 https://doi.org/10.1016/0022-1759(84)90337-5
    49 https://doi.org/10.1016/0022-1759(84)90435-6
    50 https://doi.org/10.1016/0092-8674(87)90592-7
    51 https://doi.org/10.1016/0092-8674(90)90801-k
    52 https://doi.org/10.1016/s0076-6879(87)46009-6
    53 https://doi.org/10.1073/pnas.78.12.7535
    54 https://doi.org/10.1093/oxfordjournals.bmb.a072464
    55 https://doi.org/10.1126/science.3500513
    56 https://doi.org/10.1126/science.6324343
    57 https://doi.org/10.1128/mcb.7.1.251
    58 https://doi.org/10.1172/jci111463
    59 https://doi.org/10.1210/mend-3-11-1830
    60 schema:datePublished 1993-02
    61 schema:datePublishedReg 1993-02-01
    62 schema:description Using the breast carcinoma cell line MDA-MB 468 as immunogen, we have produced six new rat monoclonal antibodies (mAbs) against the human EGF receptor (EGFR) and are investigating their use for diagnostic and therapeutic applications in cancer patients whose tumours overexpress these receptors. The mAbs (three IgG2b and one each of IgG2a, IgG1 and IgA) were selected on the basis that they bound to the extracellular domain of the EGFR and blocked growth factor-receptor interaction. Competitive assays showed that, with the exception of antibody ICR65, the mAbs bound to one of two distinct epitopes on the external domain of the EGFR. ICR65, however, cross-reacted with mAbs binding to both epitopes. All of the mAbs immunoprecipitated the 170 kDa glycoprotein from cells expressing the EGFR but not the 185 kDa product of the related c-erbB-2 proto-oncogene. Unlike EGF and TGF alpha none of the mAbs stimulated the growth of quiescent human foreskin fibroblasts but they inhibited the EGF and TGF alpha induced growth stimulation of these cells in vitro. When tested for their effect on tumour cells the mAbs were found to inhibit the growth in vitro of a number of human tumours that overexpressed the EGFR (e.g. HN5, HN6, HN15, A431, MDA-MB 468) but they were without effect on tumour cell lines expressing low or undetectable amounts of the receptor. Our initial results indicate that this new generation of antibodies which bind with high affinity to the EGFR, block growth factor-receptor interaction and inhibit the growth of human squamous carcinoma cell lines overexpressing the receptor have potential for clinical application.
    63 schema:genre research_article
    64 schema:inLanguage en
    65 schema:isAccessibleForFree true
    66 schema:isPartOf N54f3878a313540f9b870c8f35c8e975a
    67 N6063f4a80d864aef9785d8e68af866f4
    68 sg:journal.1017082
    69 schema:name The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468
    70 schema:pagination 247
    71 schema:productId N0b23fa3244294c66bfde4ab836154181
    72 N225a5c56bbd747faace954de0c49ff20
    73 N5eb23aa6e75240f9a7a63ba40cd09530
    74 N868f2ba435d6484eb19f35db5e9ac3b6
    75 N91ed49879ee34755b260a16ad51a4090
    76 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037345733
    77 https://doi.org/10.1038/bjc.1993.48
    78 schema:sdDatePublished 2019-04-11T11:55
    79 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    80 schema:sdPublisher N4f0b0f18e74f40cf9c202dbfacc0c2a2
    81 schema:url https://www.nature.com/articles/bjc199348
    82 sgo:license sg:explorer/license/
    83 sgo:sdDataset articles
    84 rdf:type schema:ScholarlyArticle
    85 N017ea951cb7c44e1bb2242e4bb4fceb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    86 schema:name Fibroblasts
    87 rdf:type schema:DefinedTerm
    88 N01e050d9faca4b0abccb373a05773336 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    89 schema:name Immunoglobulin G
    90 rdf:type schema:DefinedTerm
    91 N0b23fa3244294c66bfde4ab836154181 schema:name pubmed_id
    92 schema:value 8094290
    93 rdf:type schema:PropertyValue
    94 N225a5c56bbd747faace954de0c49ff20 schema:name readcube_id
    95 schema:value b1e69b00510c029c8b59bf64793b4ce23ca5f1fffb54f1d0db84012bd4a927b5
    96 rdf:type schema:PropertyValue
    97 N24b751acce444c6cb9d8b7af3a015be8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    98 schema:name Antibodies, Monoclonal
    99 rdf:type schema:DefinedTerm
    100 N28b0cbde4f0447828454d374aeed5426 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    101 schema:name Female
    102 rdf:type schema:DefinedTerm
    103 N3454487b040c4e9c8f57a3abba937050 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    104 schema:name Tumor Cells, Cultured
    105 rdf:type schema:DefinedTerm
    106 N4575624772df4420b36c1ec557c9c601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    107 schema:name Humans
    108 rdf:type schema:DefinedTerm
    109 N4f0b0f18e74f40cf9c202dbfacc0c2a2 schema:name Springer Nature - SN SciGraph project
    110 rdf:type schema:Organization
    111 N54f3878a313540f9b870c8f35c8e975a schema:issueNumber 2
    112 rdf:type schema:PublicationIssue
    113 N5eb23aa6e75240f9a7a63ba40cd09530 schema:name dimensions_id
    114 schema:value pub.1037345733
    115 rdf:type schema:PropertyValue
    116 N60137212c10d4889bb6323d8285b05d5 rdf:first sg:person.0637732460.22
    117 rdf:rest rdf:nil
    118 N6063f4a80d864aef9785d8e68af866f4 schema:volumeNumber 67
    119 rdf:type schema:PublicationVolume
    120 N6ba8f68ab4b84ea7b71c2ab0023c7281 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    121 schema:name Animals
    122 rdf:type schema:DefinedTerm
    123 N6c4fa3f9afef457e92fe85915e1001d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    124 schema:name Vulvar Neoplasms
    125 rdf:type schema:DefinedTerm
    126 N77a1e6ab00fb4a21a34a11d7f0fc2e24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    127 schema:name Hybridomas
    128 rdf:type schema:DefinedTerm
    129 N868f2ba435d6484eb19f35db5e9ac3b6 schema:name nlm_unique_id
    130 schema:value 0370635
    131 rdf:type schema:PropertyValue
    132 N88405fe97bce4608a2e490c89e91fa5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Receptor, ErbB-2
    134 rdf:type schema:DefinedTerm
    135 N91ed49879ee34755b260a16ad51a4090 schema:name doi
    136 schema:value 10.1038/bjc.1993.48
    137 rdf:type schema:PropertyValue
    138 N93c86e5f164e40cf90bc6040494914fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    139 schema:name Proto-Oncogene Proteins
    140 rdf:type schema:DefinedTerm
    141 Na040518ac941497787caa8ec6e24e815 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Breast Neoplasms
    143 rdf:type schema:DefinedTerm
    144 Na1b53ed9fd41457aac4e5773f4e4f3bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Mice
    146 rdf:type schema:DefinedTerm
    147 Nb01c7d260e5244cc99fb108c3ec4b6cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Epidermal Growth Factor
    149 rdf:type schema:DefinedTerm
    150 Ncf4873ba48984604b969fce661ab6ef4 rdf:first sg:person.01200253670.41
    151 rdf:rest N60137212c10d4889bb6323d8285b05d5
    152 Nd8914655bffa40188587d41192eaa605 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Cell Division
    154 rdf:type schema:DefinedTerm
    155 Ne0093110a1244df69d7355ebddace48e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    156 schema:name Rats
    157 rdf:type schema:DefinedTerm
    158 Ne428f38f637c439493d85a92fbd20c0b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    159 schema:name Cross Reactions
    160 rdf:type schema:DefinedTerm
    161 Ne725714f08eb434cbb72fcb9c07ca578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Transforming Growth Factor alpha
    163 rdf:type schema:DefinedTerm
    164 Ne9691047603441d7aa64b5bb32fd8fbc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name ErbB Receptors
    166 rdf:type schema:DefinedTerm
    167 Ne9c5d2f943144fdab3d398938695ba09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    168 schema:name Rats, Nude
    169 rdf:type schema:DefinedTerm
    170 Nf12615c3367d48ffbe5c12aca28d6bb8 rdf:first sg:person.01056410041.13
    171 rdf:rest Ncf4873ba48984604b969fce661ab6ef4
    172 Nfc00ce6ee2784562a723479697dad713 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    173 schema:name Rats, Inbred Strains
    174 rdf:type schema:DefinedTerm
    175 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    176 schema:name Medical and Health Sciences
    177 rdf:type schema:DefinedTerm
    178 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    179 schema:name Oncology and Carcinogenesis
    180 rdf:type schema:DefinedTerm
    181 sg:journal.1017082 schema:issn 0007-0920
    182 1532-1827
    183 schema:name British Journal of Cancer
    184 rdf:type schema:Periodical
    185 sg:person.01056410041.13 schema:affiliation https://www.grid.ac/institutes/grid.18886.3f
    186 schema:familyName Modjtahedi
    187 schema:givenName H
    188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01056410041.13
    189 rdf:type schema:Person
    190 sg:person.01200253670.41 schema:familyName Styles
    191 schema:givenName J M
    192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01200253670.41
    193 rdf:type schema:Person
    194 sg:person.0637732460.22 schema:familyName Dean
    195 schema:givenName C J
    196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637732460.22
    197 rdf:type schema:Person
    198 sg:pub.10.1007/bf01741322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004298551
    199 https://doi.org/10.1007/bf01741322
    200 rdf:type schema:CreativeWork
    201 sg:pub.10.1038/313745a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010441557
    202 https://doi.org/10.1038/313745a0
    203 rdf:type schema:CreativeWork
    204 https://app.dimensions.ai/details/publication/pub.1077279988 schema:CreativeWork
    205 https://app.dimensions.ai/details/publication/pub.1077337747 schema:CreativeWork
    206 https://app.dimensions.ai/details/publication/pub.1078475424 schema:CreativeWork
    207 https://app.dimensions.ai/details/publication/pub.1078868051 schema:CreativeWork
    208 https://app.dimensions.ai/details/publication/pub.1079264608 schema:CreativeWork
    209 https://app.dimensions.ai/details/publication/pub.1079500151 schema:CreativeWork
    210 https://app.dimensions.ai/details/publication/pub.1079508043 schema:CreativeWork
    211 https://app.dimensions.ai/details/publication/pub.1079509297 schema:CreativeWork
    212 https://app.dimensions.ai/details/publication/pub.1079543285 schema:CreativeWork
    213 https://app.dimensions.ai/details/publication/pub.1079767004 schema:CreativeWork
    214 https://app.dimensions.ai/details/publication/pub.1080064417 schema:CreativeWork
    215 https://app.dimensions.ai/details/publication/pub.1081564232 schema:CreativeWork
    216 https://app.dimensions.ai/details/publication/pub.1081683249 schema:CreativeWork
    217 https://doi.org/10.1002/ijc.2910450124 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044614689
    218 rdf:type schema:CreativeWork
    219 https://doi.org/10.1002/ijc.2910450219 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021662420
    220 rdf:type schema:CreativeWork
    221 https://doi.org/10.1002/jcb.240200207 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052427608
    222 rdf:type schema:CreativeWork
    223 https://doi.org/10.1002/mrd.1080270104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040872441
    224 rdf:type schema:CreativeWork
    225 https://doi.org/10.1002/path.1711490104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010503247
    226 rdf:type schema:CreativeWork
    227 https://doi.org/10.1016/0003-9861(87)90062-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001570577
    228 rdf:type schema:CreativeWork
    229 https://doi.org/10.1016/0006-291x(78)91322-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002672775
    230 rdf:type schema:CreativeWork
    231 https://doi.org/10.1016/0006-291x(85)90131-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048416200
    232 rdf:type schema:CreativeWork
    233 https://doi.org/10.1016/0022-1759(84)90337-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013930186
    234 rdf:type schema:CreativeWork
    235 https://doi.org/10.1016/0022-1759(84)90435-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045400812
    236 rdf:type schema:CreativeWork
    237 https://doi.org/10.1016/0092-8674(87)90592-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054549968
    238 rdf:type schema:CreativeWork
    239 https://doi.org/10.1016/0092-8674(90)90801-k schema:sameAs https://app.dimensions.ai/details/publication/pub.1037771370
    240 rdf:type schema:CreativeWork
    241 https://doi.org/10.1016/s0076-6879(87)46009-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037834946
    242 rdf:type schema:CreativeWork
    243 https://doi.org/10.1073/pnas.78.12.7535 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000954068
    244 rdf:type schema:CreativeWork
    245 https://doi.org/10.1093/oxfordjournals.bmb.a072464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1077677559
    246 rdf:type schema:CreativeWork
    247 https://doi.org/10.1126/science.3500513 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062618084
    248 rdf:type schema:CreativeWork
    249 https://doi.org/10.1126/science.6324343 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062636774
    250 rdf:type schema:CreativeWork
    251 https://doi.org/10.1128/mcb.7.1.251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014751899
    252 rdf:type schema:CreativeWork
    253 https://doi.org/10.1172/jci111463 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045385068
    254 rdf:type schema:CreativeWork
    255 https://doi.org/10.1210/mend-3-11-1830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064330421
    256 rdf:type schema:CreativeWork
    257 https://www.grid.ac/institutes/grid.18886.3f schema:alternateName Institute of Cancer Research
    258 schema:name Section of Immunology, Institute of Cancer Research, Sutton, Surrey, UK.
    259 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...